Mainsail Partners is honored to be named on GrowthCap’s Top 25 Private Equity Firms of 2022 list. Mainsail prioritizes investments in B2B software companies, specifically focused on vertical SaaS, Healthcare IT, Financial Technology, Infrastructure and Security Software, and select Horizontal SaaS. With a focus on bootstrapped companies, Mainsail leverages experience and resources it believes are relevant to helping founder-led software companies grow.
About GrowthCap Top 25 Private Equity Firms of 2022:
Per GrowthCap, they evaluate firms based on their ability to enact transformational sustained business expansion, prescient investment selection, transcendent firm cultures and networks; these are just a few of the reasons why an awardee may be selected for one of their publications.
GrowthCap speaks with investors and CEOs across industries, evaluates firm attributes through nomination submissions, reviews ESG commitment and studies investment performance to form a holistic view.
Read more about the nominees here.
The Top 25 Private Equity Firms of 2022 recognition presented herein is awarded by GrowthCap, a third-party that is not affiliated with Mainsail Partners or an investor in Mainsail Partners-sponsored vehicles. The recognition was awarded on 9/6/22 for the period 2022. GrowthCap assessed nominees based on written responses to questions on GrowthCap’s nomination form. The number of nominees reviewed for this recognition was not disclosed to Mainsail, and therefore, it and the percentage of nominees receiving the recognition, cannot be disclosed herein. GrowthCap’s recognition is based on its own evaluation and opinion and is not indicative of Mainsail Partners’ future performance, and does not reflect the experience of, or any rating by, Mainsail Partners’ investors. Mainsail Partners paid a fee to distribute the GrowthCap Top 25 Private Equity Firms of 2022 results. The receipt of compensation influences, and is likely to present a potential material conflict of interest, relating to the rating. There can be no assurance that other providers or surveys would reach the same conclusions as the foregoing. For more information regarding this recognition, please see the linked publication.